Inhibikase Therapeutics (IKT) Equity Average (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Equity Average data on file, last reported at $170.3 million in Q1 2026.

• Equity Average for Q1 2026 came in at $170.3 million, up 88.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $170.3 million (up 88.55% YoY), and the FY2025 annual result was $133.9 million, up 152.99% from the prior year.
• Equity Average climbed to $170.3 million in Q1 2026 per IKT's latest filing, from $122.9 million in the prior quarter.
• Over five years, Equity Average peaked at $170.3 million in Q1 2026 and troughed at $2.3 million in Q3 2024.
• A 5-year average of $47.1 million and a median of $27.3 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average plunged 86.76% in 2024, then jumped 3249.76% in 2025.
• A 5-year view of Equity Average shows it stood at $23.1 million in 2022, then plunged by 43.7% to $13.0 million in 2023, then jumped by 262.89% to $47.2 million in 2024, then soared by 160.56% to $122.9 million in 2025, then soared by 38.54% to $170.3 million in 2026.
• Business Quant data shows IKT's Equity Average at $170.3 million in Q1 2026, $122.9 million in Q4 2025, and $76.5 million in Q3 2025.